(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 71.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Syndax Pharmaceuticals's revenue in 2025 is $111,551,000.On average, 16 Wall Street analysts forecast SNDX's revenue for 2025 to be $14,821,587,324, with the lowest SNDX revenue forecast at $13,551,761,541, and the highest SNDX revenue forecast at $16,472,969,246. On average, 16 Wall Street analysts forecast SNDX's revenue for 2026 to be $31,929,034,888, with the lowest SNDX revenue forecast at $20,101,663,733, and the highest SNDX revenue forecast at $41,332,351,211.
In 2027, SNDX is forecast to generate $48,988,679,290 in revenue, with the lowest revenue forecast at $25,467,785,831 and the highest revenue forecast at $83,047,127,709.